Upstream Bio, Inc.
UPB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.32 | -0.66 | 0.00 |
| FCF Yield | -7.07% | -4.76% | -2.39% |
| EV / EBITDA | -6.69 | -19.31 | -32.72 |
| Quality | |||
| ROIC | -16.49% | -36.23% | -174.40% |
| Gross Margin | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.94 | 1.85 | 0.80 |
| Growth | |||
| Revenue 3-Year CAGR | 25.05% | 1,335,036.45% | 1,066,089.02% |
| Free Cash Flow Growth | -56.77% | -99.29% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 4.17 | 0.64 | 0.71 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 181.73 | 36.19 | 124.08 |